Clarient Set to Join Russell 3000 Index

ALISO VIEJO, Calif., June 29 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq:
CLRT), a premier anatomic pathology and molecular testing services resource
for pathologists, oncologists and the pharmaceutical industry, today announced
that the Company is set to join the broad-market Russell 3000 Index when
Russell Investments reconstitutes its comprehensive set of U.S. and global
equity indices on June 26, according to a preliminary list of additions posted
June 12 on www.russell.com.

"The addition of Clarient to the Russell index is important global recognition
of our Company's growth and value," said Ron Andrews, Clarient Vice Chairman
and Chief Executive Officer.

Annual reconstitution of Russell's U.S. indices captures the 4,000 largest
U.S. stocks as of the end of May, ranking them by total market capitalization.
Membership in the Russell 3000, which remains in place for one year, means
automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell
2000 Index as well as the appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes.

The Russell 3000 also serves as the U.S. component to the Russell Global
Index, which Russell launched in 2007.

Russell indices are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. An industry-leading $4 trillion in assets currently
are benchmarked to them. These investment tools originated from Russell's
multi-manager investment business in the early 1980s when the company saw the
need for a more objective, market-driven set of benchmarks in order to
evaluate outside investment managers. Total returns data for the Russell 3000
and other Russell Indexes is available at
http://www.russell.com/Indexes/performance/default.asp.

About Russell
Russell Investments provides strategic advice, world-class implementation,
state-of-the-art performance benchmarks and a range of institutional-quality
investment products. Russell has $136 billion in assets under management as
of March 31, 2009, and serves individual, institutional and advisor clients in
more than 40 countries. Founded in 1936, Russell is a subsidiary of The
Northwestern Mutual Life Insurance Company.

About Clarient
Clarient combines innovative diagnostic technologies with world class
pathology expertise to assess and characterize cancer. Clarient's mission is
to become the leader in cancer diagnostics by dedicating itself to
collaborative relationships with the healthcare community to translate cancer
discovery and research into better patient care. The Company's principal
customers include pathologists, oncologists, hospitals and biopharmaceutical
companies. The rise of individualized medicine as the new direction in
oncology has created the need for a centralized resource providing leading
diagnostic technologies, such as flow cytometry and molecular testing.
Clarient is that resource, having created a state-of-the-art commercial cancer
laboratory providing the most advanced oncology testing and diagnostic
services available both onsite and over the web. The Company is also
developing new, proprietary "companion" diagnostic markers for therapeutics in
breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a
Safeguard Scientifics, Inc. partner company. www.clarientinc.com

Forward Looking Statements
Certain statements herein regarding Clarient, Inc. contain forward-looking
statements that involve risks and uncertainty. Future events and the Company's
actual results could differ materially from the results reflected in these
forward-looking statements. Factors that might cause such a difference
include, but are not limited to: the Company's ability to continue to develop
and expand its diagnostic services business, the Company's ability to expand
and maintain a successful sales and marketing organization, the Company's
ability to maintain compliance with financial and other covenants under the
Company's credit facilities, limitations on the Company's ability to borrow
funds under its credit facilities based on the Company's qualified accounts
receivable and other liquidity factors, the Company's ability to obtain annual
renewals of or replacements for its credit facilities, the effects of a going
concern audit opinion on the Company's operations, the Company's ability to
successfully transition its billing function in-house from a third party
vendor, whether the conditions to payment of all or any portion of the
contingent consideration from the Company's prior sale of its instrument
systems business to Zeiss are satisfied, the Company's ability to remediate
the material weaknesses in the Company's internal control over financial
reporting, the continuation of favorable third party payer reimbursement for
laboratory tests, the Company's ability to obtain additional financing on
acceptable terms or at all, unanticipated expenses or liabilities or other
adverse events affecting cash flow, uncertainty of success in identifying and
developing new diagnostic tests or novel markers, the Company's ability to
fund development of new diagnostic tests and novel markers and the amount of
resources the Company determines to apply to novel marker development and
commercialization, failure to obtain FDA clearance or approval for particular
applications, the Company's ability to compete with other technologies and
with emerging competitors in novel cancer diagnostics and dependence on third
parties for collaboration in developing new tests, and risks detailed from
time to time in the Company's SEC reports, including quarterly reports on Form
10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience
with respect to laboratory services, revenues and results of operations may
not be indicative of future results for the reasons set forth above.

The Company does not assume any obligation to update any forward-looking
statements or other information contained in this document.

Contact:
Matt Clawson
Allen & Caron Inc
949.474.4300
matt@allencaron.com

SOURCE Clarient, Inc.

Matt Clawson of Allen & Caron Inc, +1-949-474-4300, matt@allencaron.com, for
Clarient, Inc.